Quarterly Report - Period To December 2021

Orthocell (ASX $OCC) has today published its Quarterly Report for the period ended 31 December 2021. Primary achievements include:

Phase 2a clinical study results show that OrthoATI™ is significantly more effective than steroid injection for treatment of rotator cuff tendon tears.
OrthoATI™US commercialisation plans accelerated with FDA engagement and commercial preparation to support a randomised controlled study.
Significant progress towards engaging a US market distribution partner for Striate+ dental membrane, together with promising use and feedback from key opinion leaders.
Discussions and tangible progress with the Australian TGA regarding our application for approval to supply Remplir™ in the Australian market for peripheral nerve repair.
Focused discussions with US FDA regarding the US regulatory pathway for Remplir™, with data to support expedited review and reimbursement positioning.

We have a strong balance sheet, with a closing cash balance of A$13.6m at the end of the Quarter – sufficient funds to support key regulatory approvals and our commercialisation goals. Click here to read today’s ASX release.

We detected you're visiting from Australia. Would you like to switch to the AU version of this site?